GlassScriptPhysician profile
Maggier Quinoa
NPI 1326581943
$1,084.21
in general payments reported to CMS, 2019-2025
14 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $151 · 2022: $301 · 2023: $200 · 2024: $60.76 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $602 · Education: $30.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $601.51 |
| Education | $30.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $262.92 | 2021-2025 | Jemperli, Zejula |
| Abbvie INC. | $192.72 | 2021-2024 | |
| Myriad Genetic Laboratories, INC. | $123.50 | 2022 | |
| Seagen INC. | $121.87 | 2023 | Tivdak |
| Daiichi Sankyo INC. | $88.83 | 2024-2025 | Enhertu, Datroway |
| Ethicon US, LLC | $76.89 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $56.23 | 2022-2023 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $28.73 | 2025 | Enhertu |
| Astellas Pharma US INC | $28.14 | 2025 | Veozah |
| Janssen Biotech, INC. | $26.22 | 2025 | Tecvayli, Darzalex |
| Sumitomo Pharma America, INC. | $23.62 | 2023 | Myfembree |
| Caris Mpi, INC. | $21.16 | 2025 | Mi Cancer Seek |
| Beone Medicines USA, INC. | $17.16 | 2025 | Tevimbra |
| Clovis Oncology, INC. | $16.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maggier Quinoa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.